Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hypopituitarism: early-phase trial registry
1 of 4 indexed Hypopituitarism trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Hypopituitarism: 4 US clinical trials tracked, 1 recruiting.
Hypopituitarism is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Center for Neurological Studies, running 1 of these trials.
Enrollment posture brief
Registry condition hypopituitarism
OPEN 1 | RECR 25% | LATE 1 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Hypopituitarism lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hypopituitarism on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hypopituitarism is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Growth Hormone Replacement Therapy for Retried Professional Football Players
Center for Neurological Studies
NCT04121780
An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)
Novo Nordisk A/S
NCT01009905
Testosterone and Growth Hormone for Bone Loss in Men
University of Pennsylvania
NCT00080483
Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia
Children's Hospital Los Angeles
NCT00140413
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hypopituitarism records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hypopituitarism trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hypopituitarism page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Hypopituitarism trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Center for Neurological Studies sponsors the most Hypopituitarism trials on record, review their full trial history before evaluating a specific study. See Center for Neurological Studies's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypopituitarism condition card totals 4 registered trials; most-linked intervention testosterone; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.